A Study of LY4060874 in Healthy Participants

Description

The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 16 study visits.

Conditions

Healthy Participants

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 16 study visits.

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4060874 in Healthy Participants

A Study of LY4060874 in Healthy Participants

Condition
Healthy Participants
Intervention / Treatment

-

Contacts and Locations

Dallas

Fortrea, Inc., Dallas, Texas, United States, 75247

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Are overtly healthy as determined by medical evaluation, including medical history and physical examination.
  • * Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m²), inclusive, at screening.
  • * To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China.
  • * To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participants' biological grandparents must be of exclusive Japanese descent and born in Japan.
  • * Have a history of or have been diagnosed with Type 1 or Type 2 diabetes mellitus or prediabetes.
  • * Have hemoglobin A1c (HbA1c) ≥ 5.7% or 39 millimoles/mole (mmol/mol) at screening.
  • * Have taken approved, including over the counter (OTC) or prescribed, medication or investigational medication for weight loss, including GLP-1 receptor agonists, within the previous 3 months of study screening.
  • * Have had surgical treatment for obesity.
  • * Are actively participating in a weight loss program or intend to initiate an intensive diet and/or exercise program during the study.

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Eli Lilly and Company,

1-877-CTLILLY (1-877-285-4559) or 3176154559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2025-11